CStone Pharmaceuticals has submitted a Phase Ib clinical trial application in Australia to evaluate CS5001 in combination with R-CHOP as first-line treatment for diffuse large B-cell lymphoma.
Zilovertamab vedotin combined with R-CHP achieved a 100% complete response rate in untreated diffuse large B-cell lymphoma patients in a Phase 2 trial.